Skip to content

Semaphorins 3A and 4D Levels in Heart Failure Patients

Semaphorins 3A and 4D Levels in Heart Failure Patients: Pathogenesis and Clinical Correlation

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02406716
Enrollment
120
Registered
2015-04-02
Start date
2015-04-30
Completion date
2017-05-31
Last updated
2015-04-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure

Brief summary

This study hypothesis is that Semaphorins 3A and 4D levels are overexpressed in patients with heart failure. Study protocol: Hospitallized patients with new onset or previously diagnosed heart failure will be recruited to the study. Control group will include healthy people with no medical records or chronic treatment at the same age range. After signing an informed constent form, full medical history and blood samples will be collected. A second blood sample will be collected 8 weeks later, assuming the patient was discharged and not hospitalized since than. The blood samples will be analyzed by Bnai Zion Medical Center Immunology labs for the above semaphorins levels in the heart failure group and control group. Statistical analysis will then commence for possible correlatoion with different clinical parameters.

Detailed description

In few previous published studies, Semaphorins 3A levels are overexpressed in patients with heart failure. The aim of our study is the compare semaphorin 3A and 4D in patients with acute decompansated heart failure with healthy donors. Second aim is to compare semaphorin level in the same patients in time of hospitalization and few weeks later when the heart failure presumingly controled. Statistical analysis will then commense for possible correlatoion with different clinical parameters like NYHA (new york heart association) status of the patient, lenghts of hospitalization and BNP (brain natriuretic peptide) levels at time of admition.

Interventions

Sponsors

Bnai Zion Medical Center
Lead SponsorOTHER_GOV

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
50 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

* Patients with new onset or previously diagnosed heart failure. * Heart failure diagnosis can be based on clinical judgment, echocardiography or elevated BNP levels

Exclusion criteria

* Patients with acute myocardial infarction diagnosed clinicly and labratory

Design outcomes

Primary

MeasureTime frame
Semaphrone 3A and 4D levelsone year

Secondary

MeasureTime frameDescription
BNP levelone yearBrain natriuretic peptide level in patient plasma

Contacts

Primary ContactNadav Willner, MD.
nadav.willner@gmail.com9720543249856

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026